Novartis Institutes For Bio Medical Research, Inc. is > 10% Shareholder of Intellia Therapeutics, Inc.. Currently has a direct ownership of 4.13 Million shares of NTLA, which is worth approximately $76.6 Million. The most recent transaction as insider was on Dec 12, 2017, when has been sold 1,523,000 shares (Common Stock) at a price of $18.3 per share, resulting in proceeds of $27,870,899. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.13M
0% 3M change
0% 12M change
Total Value Held $76.6 Million

Novartis Institutes for BioMedical Research, Inc. Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 12 2017
SELL
Open market or private sale
$27,870,899 $18.3 p/Share
1,523,000 Reduced 26.94%
4,129,903 Common Stock
Mar 03 2017
BUY
Other acquisition or disposition
-
79,245 Added 1.38%
5,652,903 Common Stock
May 11 2016
BUY
Open market or private purchase
$4,999,986 $18.0 p/Share
277,777 Added 4.75%
5,573,658 Common Stock
May 11 2016
BUY
Conversion of derivative security
-
5,295,881 Added 50.0%
5,295,881 Common Stock

Also insider at

FIXX
Homology Medicines, Inc. Healthcare
SURF
Surface Oncology, Inc. Healthcare
NIf

Novartis Institutes For Bio Medical Research, Inc.

> 10% Shareholder
Cambridge, MA

Track Institutional and Insider Activities on NTLA

Follow Intellia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA